This product is a box of 10 vials.
Sample Dosing Schedule:
Serious Warning: Please dose this product responsibly. If you're new to the product, or haven't taken it in some time, you need to start small. Skipping to a high dose too soon will cause incredibly unpleasant & long-lasting side effects. Most users will not need to progress through to the highest dosage level to achieve substantial results.
| Week 1 through 4 | 2.5mg per week | Initial onboarding dose |
| Week 5 through 8 | 5mg per week | Dose Escalation (if needed) |
| Week 9 through 12 | 7.5mg per week | Dose Escalation (if needed) |
| Week 13 through 16 | 10mg per week | Dose Escalation (if needed) |
| Week 17 through 20 | 12.5mg per week | Dose Escalation (if needed) |
| Week 21+ | 15mg per week | Maximum indicated dose |
What Is Tirzepatide ?
Tirzepatide was developed to fight type 2 diabetes, but it has also been shown to protect the cardiovascular system and work as a strong weight loss agent. Tirzepatide is a synthetic version of gastric inhibitory polypeptide (GIP) that also has glucagon-like peptide-1 (GLP-1) functions. This mix helps Tirzepatide lower blood sugar levels, improve insulin sensitivity, increase feelings of fullness, and speed up weight loss.
Tirzepatide is a synthetic version of gastric inhibitory polypeptide (GIP) created for its ability to trigger insulin release. This helps treat both type 2 diabetes and non-alcoholic fatty liver disease. Made of 39 amino acids, this fairly large molecule stimulates insulin release from the pancreas by binding to both GIP and GLP-1 receptors. Over longer periods, Tirzepatide can raise adiponectin levels by up to 26%. Studies show it reduces hunger, lowers insulin levels, and boosts insulin sensitivity. Together, these effects lead to major weight loss of about 11 kg (25 lbs), better glucose tolerance, less fat tissue, and lower heart disease risk.
Amino Acid Sequence:Â YE-Aib-GTFTSDYSI-Aib-LDKIAQÂ (C20 fatty acid)Â AFVQWLIAGGPSSGAPPPS
Molecular Formula:Â C225H348N48O68
Molecular Weight:Â 4813.527 g/mol
PubChem CID:Â 156588324
CAS Number:Â 2023788-19-2
Synonyms:Â P1206, LY3298176
What Does Tirzepatide Do?
In simple terms, Tirzepatide boosts insulin release from the pancreas, leading to better blood sugar control. In people with type 2 diabetes, it can lower hemoglobin A1c (HbA1c) levels by 2.4% after six months. The peptide also helps with weight loss in a way that depends on the dose, allowing people to lose up to 11 kg (25 lbs) over six months.
It's not just about increasing insulin release. Research suggests the peptide improves how pancreatic beta cells work—these are the cells that produce and release insulin. Studies indicate Tirzepatide may make beta cells better at handling insulin, leading to higher insulin levels in the blood and less stress on the cells. This could help slow down how type 2 diabetes progresses.
Tirzepatide doesn't raise insulin levels randomly. It seems to do so only when blood sugar levels are high. During fasting, it actually lowers insulin levels, which helps improve insulin sensitivity over time. It also reduces fasting levels of glucagon, a hormone that can worsen high blood sugar by affecting how the liver processes glucose. Overall, these changes explain why Tirzepatide has such a strong impact on blood sugar and HbA1c levels.
How Does Tirzepatide Work?
Tirzepatide acts on both the gastric inhibitory polypeptide receptor and the glucagon-like peptide-1 receptor. This dual action seems to work together, making Tirzepatide more effective than drugs that only target GLP-1 receptors, which are already used for type 2 diabetes. Tirzepatide binds more strongly to the GIP receptor than to the GLP-1 receptor.
Gastric inhibitory polypeptide, also called glucose-dependent insulinotropic polypeptide, is naturally made in the small intestine. It binds to the GIP receptor to reduce stomach acid and gastrin release while boosting insulin. The main role of the GIP receptor is to increase insulin after eating.
Glucagon-like peptide-1 receptors are on beta cells and in brain neurons. Like the GIP receptor, activating GLP-1 receptors boosts insulin release. Natural triggers include glucagon and GLP-1, but it also responds to several synthetic ones like dulaglutide, lithium, and oxyntomodulin. Activating GLP-1 receptors increases insulin production and release, making it a key target for new drugs. In the brain, it reduces appetite.
Activating GLP-1 receptors seems to increase the number of beta cells in the pancreas. It boosts the anti-death gene bcl-2 while lowering pro-death genes like bax and caspase-3. This improves beta cell survival and leads to more insulin.
The blend of GIP and GLP-1 receptor activity gives Tirzepatide an advantage over pure GLP-1 receptor drugs. Tirzepatide acts like natural GIP at the GIP receptor but prefers one signaling path (cAMP production) over another (β-arrestin recruitment) at the GLP-1 receptor. This difference from natural GLP-1 leads to stronger GLP-1 receptor activity without pulling the receptor inside the cell as much. The result is better GLP-1 receptor effects with Tirzepatide than with natural GLP-1 or other synthetic options. These small changes greatly boost insulin secretion, increase feelings of fullness, and reduce inflammation in fat tissue. Together, they make it a very effective anti-diabetes peptide.
Tirzepatide also seems to change adiponectin levels, raising this fat-burning hormone overall. Higher adiponectin reduces fat cell growth and boosts energy use by making mitochondria less efficient. Low levels of this hormone are linked to conditions like type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease. Higher adiponectin improves insulin sensitivity, so Tirzepatide likely affects this through multiple ways.
Hunger
Studies show Tirzepatide slows stomach emptying early on, but this effect fades over time due to the body getting used to it. These effects are like those from pure GLP-1 receptor drugs, suggesting this is mostly from its GLP-1 action, not GIP.
The stomach-slowing effect can last longer if starting with a low dose for four weeks and then increasing it. This also reduces side effects, creating a clear benefit for users. Slower stomach emptying boosts fullness, cuts hunger, and curbs food cravings. Combined with its effects on blood sugar, this can help change eating habits long-term.
Weight Loss
As mentioned, Tirzepatide is linked to significant weight loss over six months. Compared to other GLP-1 drugs like degludec, the difference is clear: Tirzepatide causes dose-based weight loss over time, while degludec and similar drugs lead to weight gain.
The GIP activation from Tirzepatide seems key to its long-term weight effects. GIP directly affects how sensitive fat cells are to insulin, likely explaining its impact on adiponectin. In short, Tirzepatide activates GIP receptors in fat cells, increasing insulin sensitivity. This reduces inflammation in fat tissue and raises adiponectin levels with its benefits. But that's not all.
Research shows GIP signaling in the brain controls feeding centers in the hypothalamus, leading to less food intake and better glucose management. This reduces body weight. So, Tirzepatide affects weight through adiponectin in fat tissue and brain changes that lower hunger via GIP receptor signaling.
Glucose-dependent insulinotropic polypeptide is another term for gastric inhibitory polypeptide (GIP).
Heart Health
Tirzepatide changes adiponectin levels. Low adiponectin is tied to atherosclerosis, obesity, and heart disease, while higher levels reduce these risks. In people with type 2 diabetes, Tirzepatide improves lipid markers, lowering triglycerides, apoC-III, and other fats. These changes likely cut heart disease risk by reducing body fat. Higher adiponectin boosts HDL (good cholesterol) and lowers triglycerides, both linked to lower heart risk. The hormone goes further by reducing scavenger receptors in immune cells and increasing cholesterol removal, strongly protecting against atherosclerosis. Higher adiponectin is linked to better diet, exercise, and some cholesterol drugs. Tirzepatide seems to have similar positive effects.
GLP-1 plays a key role in directly managing heart risks like high blood pressure, abnormal lipids, and obesity, as well as indirectly handling risks like inflammation and blood vessel issues. The direct effects relate to adiponectin, as discussed. The inflammation and vessel effects seem more straightforward.
For blood vessels, GLP-1 signaling relaxes them, lowering blood pressure and improving organ blood flow. This comes from more eNOS, the enzyme that makes nitric oxide for vessel relaxation. These benefits are stronger in people with existing heart disease or diabetes.
Inflammation strongly links to atherosclerosis. GLP-1 signaling reduces it through ways like less NF-κB activity, lower MMP-9, reduced inflammatory signals, and fewer active inflammatory cells. These effects can last up to three months after one dose of a GLP-1 receptor drug like Tirzepatide. Tirzepatide is in trials to check its medium-term effects on heart failure patients.
Curious about Tirzepatide (Mounjaro, Zepbound)?
Join our Facebook group to engage directly with thousands of others who use this product, and follow our Facebook/IG pages for hot updates and product announcements!
